Chimerix, the Durham antiviral drug developer, closed at $18.17 per share to cap its first week as a publicly traded company.
Chimerix shares slipped 3.3 percent in Friday trading after a 34-percent surge Thursday, the day the stock went public. The strong response from investors helped Chimerix raise more than $102 million by offering the stock at $14 a share.
The 13-year-old company doesn’t have a prescription drug on the market, but investors have confidence in its experimental treatments for life-threatening viral infections in patients whose immune systems have been compromised by cancer or by drugs.
Chimerix was one of two Triangle companies that made IPO news Thursday. Morrisville-based ChannelAdvisor told the Securities and Exchange Commission it expects to raise as much as $86 million through a public offering.
Chimerix expects to net about $95 million from the stock sale after paying banking fees and commissions. The 46-employee company will use the money for research and development, debt payments and general operations.